Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 2663 results

Media Release / Apr 27, 2016
Novartis receives three FDA Breakthrough Therapy Designations for Ilaris to treat rare types of Periodic Fever Syndromes
Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
Media Release / Apr 21, 2016
Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Net sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
Media Release / May 15, 2016
Major study published in NEJM confirms Novartis' Ultibro® Breezhaler® superiority over Seretide® in preventing COPD exacerbations
FLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
Media Release / Apr 29, 2016
Novartis drug Afinitor® recommended by CHMP for European Union approval to treat select GI and lung neuroendocrine tumors
If approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
Media Release / May 17, 2016
Novartis Foundation and partners launch innovative hypertension program in Vietnam
Ho Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the…
Media Release / May 17, 2016
Novartis renforce la division Pharmaceuticals par la création de deux unités d'affaires, Novartis Pharmaceuticals et Novartis Oncology, et nomme de nouveaux dirigeants à son Comité de direction
Paul Hudson devient CEO de Novartis Pharmaceuticals et Bruno Strigini devient CEO de Novartis Oncology ; David Epstein quitte Novartis Paul Hudson et Bruno Strigini sont nommés au Comité…
Media Release / May 17, 2016
Novartis fokussiert ihre Division Pharmaceuticals durch Schaffung der Geschäftseinheiten Novartis Pharmaceuticals und Novartis Oncology und beruft deren Leiter in die Geschäftsleitung von Novartis
Paul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen Paul Hudson und Bruno Strigini werden in…
Media Release / May 18, 2016
MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer
Independent Data Monitoring Committee recommends stopping the trial early as it met the primary endpoint, significantly extending progression-free survival (PFS) compared to letrozole alone, at pre-…
Media Release / May 17, 2016
Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
Paul Hudson appointed CEO, Novartis Pharmaceuticals, and Bruno Strigini appointed CEO, Novartis Oncology; David Epstein to leave Novartis Paul Hudson and Bruno Strigini appointed to the…
Media Release / May 19, 2016
Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure
Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program…